小干扰RNA向肺部的递送：有哪些新进展？
siRNA delivery to the lung: what's new?
作者信息
Merkel Olivia M, Rubinstein Israel, Kissel Thomas
机构信息
Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48201, USA; Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA; Jesse Brown VA Medical Center, Chicago, IL 60612, USA.
出版信息
Adv Drug Deliv Rev. 2014 Aug;75:112-28. doi: 10.1016/j.addr.2014.05.018. Epub 2014 Jun 5.
Abstract
RNA interference (RNAi) has been thought of as the general answer to many unmet medical needs. After the first success stories, it soon became obvious that short interfering RNA (siRNA) is not suitable for systemic administration due to its poor pharmacokinetics. Therefore local administration routes have been adopted for more successful in vivo RNAi. This paper reviews nucleic acid modifications, nanocarrier chemistry, animal models used in successful pulmonary siRNA delivery, as well as clinical translation approaches. We summarize what has been published recently and conclude with the potential problems that may still hamper the efficient clinical application of RNAi in the lung.
摘要
RNA干扰（RNAi）被认为是解决许多未满足医疗需求的通用方法。在首批成功案例出现后，很快就发现小干扰RNA（siRNA）由于其不良的药代动力学性质而不适合全身给药。因此，为了在体内更成功地实现RNAi，人们采用了局部给药途径。本文综述了核酸修饰、纳米载体化学、成功进行肺部siRNA递送所使用的动物模型以及临床转化方法。我们总结了最近发表的内容，并总结了可能仍然阻碍RNAi在肺部有效临床应用的潜在问题。
相似文献
1
siRNA delivery to the lung: what's new?小干扰RNA向肺部的递送：有哪些新进展？
Adv Drug Deliv Rev. 2014 Aug;75:112-28. doi: 10.1016/j.addr.2014.05.018. Epub 2014 Jun 5.
2
Nonviral pulmonary delivery of siRNA.非病毒肺部递送 siRNA。
Acc Chem Res. 2012 Jul 17;45(7):961-70. doi: 10.1021/ar200110p. Epub 2011 Sep 9.
3
Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration.经肺部给药后，体外和体内脂质体-聚合物杂化纳米粒中 siRNA 释放动力学的机制分析。
J Control Release. 2019 Sep 28;310:82-93. doi: 10.1016/j.jconrel.2019.08.004. Epub 2019 Aug 6.
4
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.聚乙烯亚胺在体内 RNAi 介导的基因靶向和 siRNA 递送至肺部中的应用。
Eur J Pharm Biopharm. 2011 Apr;77(3):438-49. doi: 10.1016/j.ejpb.2010.11.007. Epub 2010 Nov 18.
5
Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges.用于siRNA有效肺部递送的纳米载体：当前方法与挑战
Ther Deliv. 2019 May 1;10(5):311-332. doi: 10.4155/tde-2019-0012.
6
Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.仿生药物递送材料：探索肺表面活性剂在 siRNA 吸入治疗中的作用。
J Control Release. 2015 Dec 28;220(Pt B):642-50. doi: 10.1016/j.jconrel.2015.09.004. Epub 2015 Sep 10.
7
In vivo delivery of RNAi with lipid-based nanoparticles.利用脂质纳米颗粒体内递送 RNAi。
Annu Rev Biomed Eng. 2011 Aug 15;13:507-30. doi: 10.1146/annurev-bioeng-071910-124709.
8
Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy.用于 siRNA 吸入治疗的肺表面活性剂包被纳米凝胶的冻干和雾化
Eur J Pharm Biopharm. 2020 Dec;157:191-199. doi: 10.1016/j.ejpb.2020.09.011. Epub 2020 Oct 3.
9
Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery.雾化包裹交联壳聚糖纳米粒的 siRNA 用于肺部给药。
Int J Pharm. 2013 Oct 15;455(1-2):241-7. doi: 10.1016/j.ijpharm.2013.07.024. Epub 2013 Jul 20.
10
Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.用于 siRNA 递送的多功能 pH 敏感氨基脂质
Bioconjug Chem. 2016 Jan 20;27(1):19-35. doi: 10.1021/acs.bioconjchem.5b00538. Epub 2015 Dec 17.
引用本文的文献
1
Engineering Lipid Nanoparticles to Enhance Intracellular Delivery of Transforming Growth Factor-Beta siRNA (siTGF-β1) via Inhalation for Improving Pulmonary Fibrosis Post-Bleomycin Challenge.工程化脂质纳米颗粒以增强转化生长因子-β siRNA（siTGF-β1）的细胞内递送，通过吸入改善博来霉素攻击后的肺纤维化。
Pharmaceutics. 2025 Jan 24;17(2):157. doi: 10.3390/pharmaceutics17020157.
2
Pulmonary Delivery of Nonviral Nucleic Acid-Based Vaccines With Spotlight on Gold Nanoparticles.以金纳米颗粒为重点的非病毒核酸疫苗的肺部递送
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Jan-Feb;17(1):e70000. doi: 10.1002/wnan.70000.
3
A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).一种新的治疗前景：可吸入微米/纳米颗粒药物输送系统在肺癌中的分类、应用和挑战（综述）。
Int J Oncol. 2024 Apr;64(4). doi: 10.3892/ijo.2024.5626. Epub 2024 Feb 23.
4
Pulmonary siRNA Delivery with Sophisticated Amphiphilic Poly(Spermine Acrylamides) for the Treatment of Lung Fibrosis.复杂两亲性聚（多聚精胺丙烯酰胺）介导的肺部 siRNA 递送来治疗肺纤维化。
Small. 2024 May;20(22):e2308775. doi: 10.1002/smll.202308775. Epub 2023 Dec 21.
5
Impact of Peptide Sequence on Functional siRNA Delivery and Gene Knockdown with Cyclic Amphipathic Peptide Delivery Agents.肽序列对环状两亲肽给药载体功能性 siRNA 递呈和基因敲低的影响。
Mol Pharm. 2023 Dec 4;20(12):6090-6103. doi: 10.1021/acs.molpharmaceut.3c00455. Epub 2023 Nov 14.
6
RNA Therapeutics: A Healthcare Paradigm Shift.RNA疗法：医疗保健模式的转变。
Biomedicines. 2023 Apr 25;11(5):1275. doi: 10.3390/biomedicines11051275.
7
Inhaled drug delivery for the targeted treatment of asthma.吸入式药物输送在哮喘靶向治疗中的应用。
Adv Drug Deliv Rev. 2023 Jul;198:114858. doi: 10.1016/j.addr.2023.114858. Epub 2023 May 12.
8
Recent advances of metal-based nanoparticles in nucleic acid delivery for therapeutic applications.金属基纳米颗粒在核酸治疗应用中的最新进展。
J Nanobiotechnology. 2022 Nov 24;20(1):501. doi: 10.1186/s12951-022-01650-z.
9
Unlocking the promise of mRNA therapeutics.解锁 mRNA 疗法的潜力。
Nat Biotechnol. 2022 Nov;40(11):1586-1600. doi: 10.1038/s41587-022-01491-z. Epub 2022 Nov 3.
10
Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.用于呼吸系统疾病的吸入式小干扰RNA制剂：从基础研究到临床应用
Pharmaceutics. 2022 Jun 2;14(6):1193. doi: 10.3390/pharmaceutics14061193.
本文引用的文献
1
Tracking and treating activated T cells.追踪和治疗活化的T细胞。
J Drug Deliv Sci Technol. 2013 Jan 1;23(1):17-21. doi: 10.1016/s1773-2247(13)50002-5.
2
Influence of oligospermines architecture on their suitability for siRNA delivery.低聚精胺结构对其用于小干扰RNA递送适用性的影响。
Biomacromolecules. 2014 Apr 14;15(4):1299-310. doi: 10.1021/bm401849d. Epub 2014 Mar 4.
3
Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.载有针对 STAT3 的 siRNA 的纳米粒子的药物传递和抗癌潜力的评估：在肺癌中的体内外研究。
Toxicol Lett. 2014 Mar 21;225(3):454-66. doi: 10.1016/j.toxlet.2014.01.009. Epub 2014 Jan 17.
4
MicroRNAs -the next generation therapeutic targets in human diseases.微小 RNA - 人类疾病的下一代治疗靶点。
Theranostics. 2013 Nov 29;3(12):930-42. doi: 10.7150/thno.7026.
5
Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC.通过新型脂质体复合物配方DACC将治疗性小干扰RNA递送至肺内皮细胞。
Mol Ther. 2014 Apr;22(4):811-20. doi: 10.1038/mt.2013.291. Epub 2014 Jan 6.
6
Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury.在急性肺损伤动物模型中联合递送 HMGB-1 盒 A 肽和 S1PLyase siRNA。
J Control Release. 2014 Feb 10;175:25-35. doi: 10.1016/j.jconrel.2013.12.008. Epub 2013 Dec 18.
7
Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.小干扰RNA介导的分选连接蛋白1缺失促进吉非替尼耐药人肺癌细胞系中肝细胞生长因子诱导的间质-上皮转化内吞作用和间质-上皮转化磷酸化的证据。
Int J Oncol. 2014 Feb;44(2):412-26. doi: 10.3892/ijo.2013.2194. Epub 2013 Nov 28.
8
RNAi Therapeutic Platforms for Lung Diseases.用于肺部疾病的 RNAi 治疗平台。
Pharmaceuticals (Basel). 2013 Feb 6;6(2):223-50. doi: 10.3390/ph6020223.
9
A novel platform to enable inhaled naked RNAi medicine for lung cancer.一种用于肺癌吸入式裸RNA干扰药物的新型平台。
Sci Rep. 2013 Nov 25;3:3325. doi: 10.1038/srep03325.
10
Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis.钠依赖性磷酸盐共转运蛋白2b（NPT2b）的敲低可抑制肺癌发生。
PLoS One. 2013 Oct 23;8(10):e77121. doi: 10.1371/journal.pone.0077121. eCollection 2013.
Zotero 插件